NEWS!

New Post Public Reply Private Reply Replies (1) Message Board

buccaneer1961

May 27, 2013 at 8:13 PM

NEWS!

Cellceutix to Present Poster on Novel Anti-Cancer Drug at Annual ASCO Meeting

BEVERLY, MA –May 28, 2013- Cellceutix Corporation (OTCBB: CTIX) (the "Company"), a clinical stage biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases, announces today that it will be presenting a poster on the company’s p53-activating drug, Kevetrin, at the 2013 American Society of Clinical Oncology ("ASCO") Annual Meeting being held in Chicago, Illinois from May 31 through June 4, 2013.

An abstract of the poster, titled, "A phase I, dose-escalation, safety, pharmacokinetic, pharmacodynamic study of thioureidobutyronitrile, a novel p53 targeted therapy, in patients with advanced solid tumors," is now available on the ASCO website at http://abstracts2.asco.org/AbstView_132_113150.html .

“We will be presenting the most recent data available from the clinical trials of Kevetrin hosted at Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center,” said Dr. Krishna Menon, Chief Scientific Officer at Cellceutix. “We are acutely aware that the oncology community and shareholders have a strong interest regarding schedule, maximum tolerated dose and potential efficacy of Kevetrin, given its uniqueness and potential. The laboratory informed us that additional samples were required for analysis of Kevetrin’s affect on biomarker p21, an early-stage indicator of efficacy. Those samples have been supplied by the hospital with more to be delivered as the trial progresses. We are hopeful that data will be available in time for ASCO.”

Leo Ehrlich, Chief Executive Officer at Celleutix, added, “To keep shareholders abreast of pipeline developments, manufacturing and scheduling is near complete for the Phase II clinical trial of our oral anti-psoriasis drug Prurisol. We anticipate the Proof of Concept trial to begin in August and take eight weeks to be completed. Given the recent market enthusiasm towards Celgene’s research of Apremilast, we are eager to commence our clinical research of Prurisol.”

“Additionally, I am pleased to inform shareholders that we plan to soon announce a new novel drug specifically designed for the treatment of leukemias as we make the next progression in growing our cancer drug franchise,” concluded Mr. Ehrlich.

About Kevetrin™

As a completely new class of chemistry in medicine, Kevetrin™ has significant potential to be a major breakthrough in the treatment of solid tumors. Mechanism of action studies showed Kevetrin's unique ability to affect both wild and mutant types of p53 (often referred to as the "Guardian Angel Gene" or the "Guardian Angel of the Human Genome") and that Kevetrin strongly induced apoptosis (cell death), characterized by activation of Caspase 3 and cleavage of PARP. Activation of p53 also induced apoptosis by inducing the expression of p53 target gene PUMA. p53 is an important tumor suppressor that acts to restrict proliferation by inducing cell cycle checkpoints, apoptosis, or cellular senescence.

In more than 50 percent of all human carcinomas, p53 is limited in its anti-tumor activities by mutations in the protein itself. Currently, there are greater than 10 million people with tumors that contain inactivated p53, while a similar number have tumors in which the p53 pathway is partially abrogated by inactivation of other signaling components. This has left cancer researchers with the grand challenge of searching for therapies that could restore the protein's protective function, which Kevetrin appears to be doing the majority of the time.

Further information on the clinical trial, titled "A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin (Thioureidobutyronitrile) Administered Intravenously, in Patients With Advanced Solid Tumors," is available at: http://clinicaltrials.gov/ct2/show/NCT0166400...amp;rank=1

About Cellceutix

Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company under the symbol "CTIX". It is an emerging bio-pharmaceutical company focused on the development of its pipeline of compounds targeting areas of unmet medical need. Our flagship compound, Kevetrin™, is an anti-cancer drug which has demonstrated the ability in pre-clinical studies to regulate the p53 pathway and attack cancers which have proven resistant to today's cancer therapies (drug-resistant cancers). Cellceutix also owns the rights to seven other drug compounds, including KM-133, which is in development for psoriasis, and KM-391 for the treatment of the core symptoms of autism. More information is available on the Cellceutix web site at www.cellceutix.com.

Safe Harbor Forward-Looking Statements

To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Factors that may impact Cellceutix's success are more fully disclosed in Cellceutix's most recent public filings with the U.S. Securities and Exchange Commission.

Cellceutix Corp.
Leo Ehrlich
(978) 236-8717
info@cellceutix.com


Copyright © 2013 Cellceutix Corporation, All rights reserved. You requested to receive email alerts about Cellceutix at our website www.cellceutix.com Our mailing address is: Cellceutix Corporation 100 Cumming Center, Suite 151-B Beverly , MA 01915 Add us to your address book

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AI Revenue Missteps Shake Semiconductor Stocks

Nervous Times for Semiconductor Stocks When the semiconductor sector started October like a high-speed train, I thought we might sail through this month without hitting turbulence. But then, in trotted some shaky AI revenue numbers, and bam, the whole sector took a hit off its October highs. The semiconductor stocks, led by giants like Taiwan Semiconductor Manufacturing...

RingConn Smart Ring Gains Key FDA 510(k) Clearance

FDA Clearance: A Major Step for RingConn In a space where every tiny gadget-maker is desperately clawing for a regulatory nod, RingConn—a venture born from Shenzhen Ninenovo Technology Limited—has snagged an FDA 510(k) clearance (Clearance No. K260490) for their wearable Smart Ring that measures blood oxygen levels non-invasively. October 10, 2026, marked the day when...

Kexing Biopharm Expands Global Reach at CPHI Milan

Kexing Biopharm's Showstopper Moment in Milan Call it a strategic blowout or just audacious timing—Kexing Biopharm's move at the CPHI Milan 2026 has painted a clear picture. From October 6th to 8th, Milan was the stage where Kexing rolled out its showcase, bragging about a pipeline that screams innovation and possibility. And let’s be honest, their timing couldn’t...

Young Visionaries Win Junior Medals at STARMUS VIII

Fresh from the Canary Islands' shores, STARMUS VIII has lifted the veil on two young powerhouses shaping tomorrow—Valeria Corrales and Aneeshwar Kunchala. These two have snagged coveted honors, crowning them as champions of their generation. Igniting Passion for Science and the Environment Valeria Corrales isn't just another face in the crowd; she’s the force behind a...

KAPSARC Drives Energy Dialogue at WPC in Riyadh

Defining Energy Horizons in Riyadh Mark those calendars, because as the global energy crowd descends on Riyadh from October 11 to 15, 2026, KAPSARC steps into the spotlight. As the National Partner at the 25th World Petroleum Congress (WPC), they're not just warming the bench—they're playing every position, shaking up the field of energy. Paving the Pathways with...

Buying Land in Greeneville: Avoiding Costly Mistakes

Diving Headfirst into Raw Land Purchases Buying land isn't like your typical house flip in Greeneville, Tennessee. It's a whole different ballgame out there. You might think you're just purchasing a piece of Mother Earth, but you got to know there's more beneath the surface—quite literally—before you sign anything. You can go from a promising adventure to a...

Phoenix Scholar Examines AI and Institutional Trust

A Thoughtful Look at Trust and Technology We're staring at an issue here that dives deep into the guts of how technology, AI in particular, is reshaping our professional landscape. The latest issue of the Phoenix Scholar, a publication from the University of Phoenix College of Doctoral Studies, is tackling big questions. It's that kind of brainy reading where you untangle...

Amap, Sands China Unleash Tutu Robots for Resort Duty

Tutu Robots Usher in a New Technological Era for Sands China Alright, let's dive into some tech that feels out of a sci-fi movie and see what Sands China and Amap have cooked up as they introduce the Tutu robot dogs to Sands Resorts Macau. These aren't your run-of-the-mill gadgets—they're futuristic tour guides ready to rewire visitor experiences. The delivery ceremony...

Arrvel's Thermal Printers: Aiming at E-Com Sellers

Arrvel's Thermal Printing Push: An Overview No one would have pegged tiny thermal label printers as game-changers, but here we are. Arrvel's new lineup of thermal printers is shaking up the world for anyone who's ever had to slap on a shipping label or get inventory organized. They're targeting e-commerce folks and small businesses, which sounds like the right move as...

Tchah Sup Kim: A Retrospective at KCCNY in 2026

A Glimpse into Tchah Sup Kim's Legacy Stumble into the world of Tchah Sup Kim (1940–2022) this fall at the Korean Cultural Center New York. Kim's posthumous retrospective, "The Key to a New World," brings together over 130 of his works alongside archival materials, offering a comprehensive dive into a mind that spent decades between New York and Korea. The exhibit,...